Structural domain of apolipoprotein A-I involved in its interaction with cells.
Apolipoprotein A-I (apo A-I) is the major protein constituent of high-density lipoprotein (HDL), the lipoprotein fraction which mediates the reverse cholesterol transport. This apolipoprotein plays an important role in the binding of HDL to cells and participates in the efflux of cellular cholesterol. We have recently compared six different genetic variants of apo A-I and found that the apo A-I (Pro 165-->Arg) mutant is defective in promoting cellular cholesterol efflux from murine adipocytes and peritoneal macrophages and we have proposed that this region of apo A-I may be involved in their interaction with cells. To confirm this hypothesis, four monoclonal antibodies (mAbs) specific for apo A-I were used to study the inhibition of the interaction of palmitoyloleoylphosphatidylcholine (POPC): apoA-I complexes with HeLa cells and adipocytes. Among these antibodies, the apo A-I epitope recognized by the A44 mAb lies in the COOH terminal region (amino acid residues 149-186) including the proposed region. The antibodies A05, and A03 react with residues 25-82, 135-140, respectively and the A11 mAb corresponds to a discontinuous epitope at residues 99-105 and 126-132. Our results show clearly that the A44 and A05 mAbs reduce both the binding to HeLa cells and the cholesterol efflux from adipocytes. The inhibition of POPC: apoA-I complexes binding to both cell types is more strictly observed with the Fab fragments of monoclonal antibodies A44 and A05. Partial cotitration curves of these mAbs in a solid phase assay (RIA), indicated partial competition between these two antibodies. We propose a structural model for the POPC: apoA-I complexes where the N-terminal domain of one apo A-I molecule is in close spatial relationship with the C-terminal domain of the adjacent apo A-I molecule. We therefore suggest that the domain around amino acid 165 of apo A-I and which is recognized by mAb A44 (149-186) forms or contains some specific regions which mediate selectively the interaction with the binding site of cells and is involved in the efflux of cellular cholesterol.
Luchoomun
J
J
Service d'Etude et de Recherche sur les Lipoprotéines et l'Athérosclérose, INSERM U325, Institut Pasteur, Lille, France.
Theret
N
N
Clavey
V
V
Duchateau
P
P
Rosseneu
M
M
Brasseur
R
R
Denefle
P
P
Fruchart
J C
JC
Castro
G R
GR
D017667:Adipocytes / Q000378:metabolism; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D016632:Apolipoprotein A-I / Q000737:chemistry / Q000276:immunology / Q000378:metabolism*; D001665:Binding Sites; D001667:Binding, Competitive; D002784:Cholesterol / Q000378:metabolism; D000939:Epitopes / Q000276:immunology; D006367:HeLa Cells / Q000378:metabolism; D006801:Humans; D010713:Phosphatidylcholines / Q000737:chemistry / Q000378:metabolism
D000911:Antibodies, Monoclonal; D016632:Apolipoprotein A-I; D000939:Epitopes; D010713:Phosphatidylcholines; D002784:Cholesterol; C028694:1-palmitoyl-2-oleoylphosphatidylcholine